Cutler Group’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $2K | Hold |
193
| – | – | ﹤0.01% | 1873 |
|
|
2023
Q4 | $1K | Hold |
193
| – | – | ﹤0.01% | 3373 |
|
|
2023
Q3 | $1K | Hold |
193
| – | – | ﹤0.01% | 3577 |
|
|
2023
Q2 | $1K | Hold |
193
| – | – | ﹤0.01% | 3349 |
|
|
2023
Q1 | $2K | Hold |
193
| – | – | ﹤0.01% | 3198 |
|
|
2022
Q4 | $6K | Hold |
193
| – | – | ﹤0.01% | 3056 |
|
|
2022
Q3 | $9K | Sell |
193
-40
| -17% | -$2.38K | ﹤0.01% | 3202 |
|
|
2022
Q2 | $13K | Sell |
233
-248
| -52% | -$15.6K | ﹤0.01% | 3016 |
|
|
2022
Q1 | $38K | Sell |
481
-154
| -24% | -$22.8K | ﹤0.01% | 2488 |
|
|
2021
Q4 | $128K | Buy |
635
+222
| +54% | +$48.2K | 0.01% | 1665 |
|
|
2021
Q3 | $111K | Hold |
413
| – | – | 0.01% | 1829 |
|
|
2021
Q2 | $106K | Hold |
413
| – | – | ﹤0.01% | 1829 |
|
|
2021
Q1 | $124K | Buy |
413
+306
| +286% | +$95.2K | 0.01% | 1605 |
|
|
2020
Q4 | $27K | Hold |
107
| – | – | ﹤0.01% | 2461 |
|
|
2020
Q3 | $26K | Hold |
107
| – | – | ﹤0.01% | 2261 |
|
|
2020
Q2 | $37K | Sell |
107
-106
| -50% | -$33.1K | ﹤0.01% | 1951 |
|
|
2020
Q1 | $57K | Buy |
213
+193
| +965% | +$59.7K | ﹤0.01% | 1651 |
|
|
2019
Q4 | $6K | Sell |
20
-47
| -70% | -$13.6K | ﹤0.01% | 2946 |
|
|
2019
Q3 | $18K | Sell |
67
-6
| -8% | -$2.2K | ﹤0.01% | 2260 |
|
|
2019
Q2 | $39K | Sell |
73
-27
| -27% | -$13.5K | ﹤0.01% | 1731 |
|
|
2019
Q1 | $50K | Buy |
100
+54
| +117% | +$32K | 0.01% | 1426 |
|
|
2018
Q4 | $22K | Sell |
46
-240
| -84% | -$145K | ﹤0.01% | 2046 |
|
|
2018
Q3 | $261K | Sell |
286
-533
| -65% | -$455K | 0.02% | 717 |
|
|
2018
Q2 | $599K | Sell |
819
-67
| -8% | -$77.3K | 0.05% | 381 |
|
|
2018
Q1 | $1.41M | Buy |
886
+663
| +297% | +$854K | 0.12% | 158 |
|
|
2017
Q4 | $199K | Buy |
223
+178
| +396% | +$105K | 0.01% | 963 |
|
|
2017
Q3 | $16K | Buy |
+45
| New | +$14.1K | ﹤0.01% | 3341 |
|
|
2017
Q1 | – | Sell |
-532
| Closed | -$120K | – | 6932 |
|
|
2016
Q4 | $97K | Buy |
532
+213
| +67% | +$43.3K | ﹤0.01% | 1941 |
|
|
2016
Q3 | $82K | Buy |
319
+180
| +129% | +$46.3K | ﹤0.01% | 1976 |
|
|
2016
Q2 | $29K | Buy |
139
+100
| +256% | +$22.4K | ﹤0.01% | 2966 |
|
|
2016
Q1 | $8K | Sell |
39
-547
| -93% | -$105K | ﹤0.01% | 4341 |
|
|
2015
Q4 | $148K | Buy |
+586
| New | +$121K | 0.01% | 1431 |
|
Other funds holding NKTR
DTC
MAM
TCM
SCM
Cutler Group's NKTR Position: Q1 2024 in Review
Cutler Group held its Nektar Therapeutics (NKTR) position steady in Q1 2024 at 193 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #1873.
Cutler Group first reported a position in NKTR in Q4 2015 and has held it in 32 quarters since. The position peaked at $1.41M in Q1 2018. 124 funds tracked by Wall St. Rank hold NKTR as of Q1 2024.
- Cutler Group held 193 shares of Nektar Therapeutics worth $2K as of Q1 2024.
- Cutler Group left its Nektar Therapeutics share count unchanged in Q1 2024.
- Nektar Therapeutics made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1873 holding.
- Cutler Group first reported a position in Nektar Therapeutics in Q4 2015 and has held it in 32 quarters since.
- Cutler Group's Nektar Therapeutics position peaked at $1.41M in Q1 2018.
- 124 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2024.
Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.